Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 10/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.49 |
| ▸ | GSK3B | P49841 | 6/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 5/20 | 0.48 |
| ▸ | AKT1 | P31749 | 5/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.48 |
| ▸ | PRKG2 | Q13237 | 5/20 | 0.48 |
| ▸ | PRKG1 | Q13976 | 5/20 | 0.48 |
| ▸ | PKN2 | Q16513 | 5/20 | 0.48 |
| ▸ | GSK3A | P49840 | 5/20 | 0.48 |
| ▸ | NEK4 | P51957 | 4/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.48 |
| ▸ | SGK2 | Q9HBY8 | 4/20 | 0.48 |
| ▸ | PRKACA | P17612 | 4/20 | 0.48 |
| ▸ | PRKX | P51817 | 4/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10061708 | 0.90 | ROCK2 (0.47) | ROCK1ROCK2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14277949 | 0.90 | ROCK2 (0.47) | ROCK1ROCK2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL9931517 | 0.79 | ROCK2 (0.61) | ROCK1ROCK2GSK3BCLK4RPS6KA5 | |
| SCHEMBL9931061 | 0.79 | ROCK2 (0.61) | ROCK1ROCK2GSK3BCLK4RPS6KA5 | |
| SCHEMBL1697693 | 0.79 | ROCK2 (0.61) | ROCK1ROCK2GSK3BCLK4RPS6KA5 | |
| SCHEMBL3103847 | 0.79 | ROCK2 (0.78) | ROCK1ROCK2GSK3BCLK4RPS6KA5 | |
| SCHEMBL185572 | 0.78 | ALDH1A1 (0.68) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7081080 | 0.77 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8403294 | 0.77 | ALDH1A1 (0.53) | RPS6KB1MAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL1697588 | 0.77 | CYP1A2 (0.65) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588451-B1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-30 | — | — | EP | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | ROCK1 3603/4885ROCK2 3663/4885GSK3B 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.